메뉴 건너뛰기
Gynecologic Oncology
Volumn 118, Issue 1, 2010, Pages 95-96
Letter to the Editor referring to the manuscript entitled: "Phase II trial of trastuzumab in women with advanced or recurrent HER-positive endometrial carcinoma: a Gynecologic Oncology Group study" recently reported by Fleming et al., (Gynecol Oncol., 116;15-20;2010)
Author keywords

[No Author keywords available]
Indexed keywords

TRASTUZUMAB;
EID: 77953289073     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.01.043     Document Type: Letter
Times cited : (35)
References (6)
  • 1
    • 70749097152 scopus 로고    scopus 로고
    • Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study
    • Fleming G.F., Sill M.W., Darcy K.M., et al. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 116 1 (2010) 15-20
    • (2010) Gynecol Oncol , vol.116 , Issue.1 , pp. 15-20
    • Fleming, G.F.1    Sill, M.W.2    Darcy, K.M.3
  • 2
    • 0029991439 scopus 로고    scopus 로고
    • Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
    • Baselga J., Tripathy D., Mendelsohn J., et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14 3 (1996) 737-744
    • (1996) J Clin Oncol , vol.14 , Issue.3 , pp. 737-744
    • Baselga, J.1    Tripathy, D.2    Mendelsohn, J.3
  • 3
    • 0032850677 scopus 로고    scopus 로고
    • Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
    • Cobleigh M.A., Vogel C.L., Tripathy D., et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17 9 (1999) 2639-2648
    • (1999) J Clin Oncol , vol.17 , Issue.9 , pp. 2639-2648
    • Cobleigh, M.A.1    Vogel, C.L.2    Tripathy, D.3
  • 4
    • 33745100721 scopus 로고    scopus 로고
    • Use of trastuzumab in the treatment of metastatic endometrial cancer
    • Jewell E., Secord A.A., Brotherton T., and Berchuck A. Use of trastuzumab in the treatment of metastatic endometrial cancer. Int J Gynecol Cancer 16 (2006) 1370-1373
    • (2006) Int J Gynecol Cancer , vol.16 , pp. 1370-1373
    • Jewell, E.1    Secord, A.A.2    Brotherton, T.3    Berchuck, A.4
  • 5
    • 33749144509 scopus 로고    scopus 로고
    • HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications
    • Villella J.A., Cohen S., Smith D.H., Hibshoosh H., and Hershman D. HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications. Int J Gynecol Cancer 16 (2006) 1897-1902
    • (2006) Int J Gynecol Cancer , vol.16 , pp. 1897-1902
    • Villella, J.A.1    Cohen, S.2    Smith, D.H.3    Hibshoosh, H.4    Hershman, D.5
  • 6
    • 46749152126 scopus 로고    scopus 로고
    • Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu
    • Santin A.D., Bellone S., Roman J.J., McKenney J.K., and Pecorelli S. Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. Int J Gynaecol Obstet 102 (2008) 128-131
    • (2008) Int J Gynaecol Obstet , vol.102 , pp. 128-131
    • Santin, A.D.1    Bellone, S.2    Roman, J.J.3    McKenney, J.K.4    Pecorelli, S.5

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.